Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Non-coding RNAs as potential therapeutic targets in breast cancer.

Tomar D, Yadav AS, Kumar D, Bhadauriya G, Kundu GC.

Biochim Biophys Acta Gene Regul Mech. 2019 Apr 29. pii: S1874-9399(19)30016-1. doi: 10.1016/j.bbagrm.2019.04.005. [Epub ahead of print] Review.

PMID:
31048026
2.

Breast cancer stem cells: Biology and therapeutic implications.

Butti R, Gunasekaran VP, Kumar TVS, Banerjee P, Kundu GC.

Int J Biochem Cell Biol. 2019 Feb;107:38-52. doi: 10.1016/j.biocel.2018.12.001. Epub 2018 Dec 5.

PMID:
30529656
3.

A biodegradable fluorescent nanohybrid for photo-driven tumor diagnosis and tumor growth inhibition.

Prasad R, Chauhan DS, Yadav AS, Devrukhkar J, Singh B, Gorain M, Temgire M, Bellare J, Kundu GC, Srivastava R.

Nanoscale. 2018 Oct 18;10(40):19082-19091. doi: 10.1039/c8nr05164j.

PMID:
30288516
4.

Impact of semaphorin expression on prognostic characteristics in breast cancer.

Butti R, Kumar TV, Nimma R, Kundu GC.

Breast Cancer (Dove Med Press). 2018 May 31;10:79-88. doi: 10.2147/BCTT.S135753. eCollection 2018. Review.

5.

The Biology and Therapeutic Implications of Tumor Dormancy and Reactivation.

Yadav AS, Pandey PR, Butti R, Radharani NNV, Roy S, Bhalara SR, Gorain M, Kundu GC, Kumar D.

Front Oncol. 2018 Mar 19;8:72. doi: 10.3389/fonc.2018.00072. eCollection 2018. Review.

6.

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.

Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC.

Mol Cancer. 2018 Feb 19;17(1):34. doi: 10.1186/s12943-018-0797-x. Review.

7.

Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway.

Kumar D, Haldar S, Gorain M, Kumar S, Mulani FA, Yadav AS, Miele L, Thulasiram HV, Kundu GC.

BMC Cancer. 2018 Jan 8;18(1):52. doi: 10.1186/s12885-017-3876-2.

8.

Green synthesis of selenium nanoparticles using Acinetobacter sp. SW30: optimization, characterization and its anticancer activity in breast cancer cells.

Wadhwani SA, Gorain M, Banerjee P, Shedbalkar UU, Singh R, Kundu GC, Chopade BA.

Int J Nanomedicine. 2017 Sep 13;12:6841-6855. doi: 10.2147/IJN.S139212. eCollection 2017.

9.

p53 gain-of-function mutations increase Cdc7-dependent replication initiation.

Datta A, Ghatak D, Das S, Banerjee T, Paul A, Butti R, Gorain M, Ghuwalewala S, Roychowdhury A, Alam SK, Das P, Chatterjee R, Dasgupta M, Panda CK, Kundu GC, Roychoudhury S.

EMBO Rep. 2017 Nov;18(11):2030-2050. doi: 10.15252/embr.201643347. Epub 2017 Sep 8.

10.

Effectiveness of Preoperative Lymphoscintigraphy for the Detection of Cervical Lymph Node Metastasis in Patients with Oral Squamous Cell Carcinoma.

Habib MA, Rahman QB, Hossain S, Imon AA, Kundu GC.

Ann Maxillofac Surg. 2017 Jan-Jun;7(1):30-36. doi: 10.4103/ams.ams_176_16.

11.

MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2.

Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, Krishna Dhali G, Chowdhury A, Schmittgen TD, Kundu GC, Banerjee S.

Cell Death Dis. 2017 Mar 30;8(3):e2706. doi: 10.1038/cddis.2017.123.

12.

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.

Kumar D, Gorain M, Kundu G, Kundu GC.

Mol Cancer. 2017 Jan 30;16(1):7. doi: 10.1186/s12943-016-0578-3. Review.

13.

Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma.

Dai X, Ahn KS, Wang LZ, Kim C, Deivasigamni A, Arfuso F, Um JY, Kumar AP, Chang YC, Kumar D, Kundu GC, Magae J, Goh BC, Hui KM, Sethi G.

Mol Cancer Ther. 2016 Dec;15(12):2966-2976. Epub 2016 Oct 7.

14.

Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.

Kumar D, Kumar S, Gorain M, Tomar D, Patil HS, Radharani NNV, Kumar TVS, Patil TV, Thulasiram HV, Kundu GC.

J Invest Dermatol. 2016 Dec;136(12):2462-2474. doi: 10.1016/j.jid.2016.07.024. Epub 2016 Jul 29.

15.

Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells.

Mukherjee S, Manna A, Bhattacharjee P, Mazumdar M, Saha S, Chakraborty S, Guha D, Adhikary A, Jana D, Gorain M, Mukherjee SA, Kundu GC, Sarkar DK, Das T.

Oncogene. 2016 Sep 15;35(37):4937-48. doi: 10.1038/onc.2016.26. Epub 2016 Feb 29.

PMID:
26923331
16.

Diosgenin Functionalized Iron Oxide Nanoparticles as Novel Nanomaterial Against Breast Cancer.

Ghosh S, More P, Derle A, Kitture R, Kale T, Gorain M, Avasthi A, Markad P, Kundu GC, Kale S, Dhavale DD, Bellare J, Chopade BA.

J Nanosci Nanotechnol. 2015 Dec;15(12):9464-72.

PMID:
26682367
17.

Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin.

Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC.

Oncogene. 2015 Oct 16;34(42):5408-10. doi: 10.1038/onc.2015.315. No abstract available.

PMID:
26473949
18.

Comparative Characterization of Cardiac Development Specific microRNAs: Fetal Regulators for Future.

Rustagi Y, Jaiswal HK, Rawal K, Kundu GC, Rani V.

PLoS One. 2015 Oct 14;10(10):e0139359. doi: 10.1371/journal.pone.0139359. eCollection 2015.

19.

Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes.

Nanjappa V, Renuse S, Sathe GJ, Raja R, Syed N, Radhakrishnan A, Subbannayya T, Patil A, Marimuthu A, Sahasrabuddhe NA, Guerrero-Preston R, Somani BL, Nair B, Kundu GC, Prasad TK, Califano JA, Gowda H, Sidransky D, Pandey A, Chatterjee A.

Cancer Biol Ther. 2015;16(11):1593-603. doi: 10.1080/15384047.2015.1078022. Epub 2015 Sep 21.

20.

Cross-talk between endoplasmic reticulum (ER) stress and the MEK/ERK pathway potentiates apoptosis in human triple negative breast carcinoma cells: role of a dihydropyrimidone, nifetepimine.

Ghosh S, Adhikary A, Chakraborty S, Bhattacharjee P, Mazumder M, Putatunda S, Gorain M, Chakraborty A, Kundu GC, Das T, Sen PC.

J Biol Chem. 2015 Feb 13;290(7):3936-49. doi: 10.1074/jbc.M114.594028. Epub 2014 Dec 19.

21.

The potential of class 3 semaphorins as both targets and therapeutics in cancer.

Mishra R, Kumar D, Tomar D, Chakraborty G, Kumar S, Kundu GC.

Expert Opin Ther Targets. 2015 Mar;19(3):427-42. doi: 10.1517/14728222.2014.986095. Epub 2014 Nov 29. Review.

PMID:
25434284
22.

Osteopontin as a therapeutic target for cancer.

Bandopadhyay M, Bulbule A, Butti R, Chakraborty G, Ghorpade P, Ghosh P, Gorain M, Kale S, Kumar D, Kumar S, Totakura KV, Roy G, Sharma P, Shetti D, Soundararajan G, Thorat D, Tomar D, Nalukurthi R, Raja R, Mishra R, Yadav AS, Kundu GC.

Expert Opin Ther Targets. 2014 Aug;18(8):883-95. doi: 10.1517/14728222.2014.925447. Epub 2014 Jun 4. Review.

PMID:
24899149
23.

Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis.

Mishra R, Thorat D, Soundararajan G, Pradhan SJ, Chakraborty G, Lohite K, Karnik S, Kundu GC.

Oncogene. 2015 Mar 19;34(12):1584-95. doi: 10.1038/onc.2014.79. Epub 2014 Apr 14.

PMID:
24727891
24.

Biocompatible amphiphilic pentablock copolymeric nanoparticles for anti-cancer drug delivery.

Byagari K, Shanavas A, Rengan AK, Kundu GC, Srivastava R.

J Biomed Nanotechnol. 2014 Jan;10(1):109-19.

PMID:
24724503
25.

Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers.

Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, Karnik S, Doke S, Kundu GC.

Oncol Lett. 2013 Dec;6(6):1559-1564. Epub 2013 Oct 1.

26.

One-pot fluorescent labeling protocol for complex hydroxylated bioactive natural products.

Haldar S, Kumar S, Kolet SP, Patil HS, Kumar D, Kundu GC, Thulasiram HV.

J Org Chem. 2013 Oct 18;78(20):10192-202. doi: 10.1021/jo401559t. Epub 2013 Oct 10.

PMID:
24079457
27.

Functional characterization of stromal osteopontin in melanoma progression and metastasis.

Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M, Kundu GC.

PLoS One. 2013 Jul 23;8(7):e69116. doi: 10.1371/journal.pone.0069116. Print 2013.

28.

Biological synthesis of silver nanoparticles using the fungus Humicola sp. and evaluation of their cytoxicity using normal and cancer cell lines.

Syed A, Saraswati S, Kundu GC, Ahmad A.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Oct;114:144-7. doi: 10.1016/j.saa.2013.05.030. Epub 2013 May 25.

PMID:
23770500
29.

Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin.

Kale S, Raja R, Thorat D, Soundararajan G, Patil TV, Kundu GC.

Oncogene. 2014 May 1;33(18):2295-306. doi: 10.1038/onc.2013.184. Epub 2013 Jun 3. Erratum in: Oncogene. 2015 Oct 16;34(42):5408-10.

PMID:
23728342
30.

Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis.

Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu GC.

Oncogene. 2014 Apr 17;33(16):2053-64. doi: 10.1038/onc.2013.171. Epub 2013 Jun 3.

PMID:
23728336
31.

Modified dipeptide-based nanoparticles: vehicles for targeted tumor drug delivery.

Panda JJ, Kaul A, Kumar S, Alam S, Mishra AK, Kundu GC, Chauhan VS.

Nanomedicine (Lond). 2013 Dec;8(12):1927-42. doi: 10.2217/nnm.12.201. Epub 2013 Feb 12.

PMID:
23398497
32.

Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway.

Kumar S, Patil HS, Sharma P, Kumar D, Dasari S, Puranik VG, Thulasiram HV, Kundu GC.

Curr Mol Med. 2012 Sep;12(8):952-66.

PMID:
22804248
33.

Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model.

Chakraborty G, Kumar S, Mishra R, Patil TV, Kundu GC.

PLoS One. 2012;7(3):e33633. doi: 10.1371/journal.pone.0033633. Epub 2012 Mar 20.

34.

Osteopontin: a potentially important therapeutic target in cancer.

Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC.

Expert Opin Ther Targets. 2011 Sep;15(9):1113-26. doi: 10.1517/14728222.2011.594438. Epub 2011 Jul 25. Review.

PMID:
21718227
35.

Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin α(v)β(3) interaction.

Prakash M, Kale S, Ghosh I, Kundu GC, Datta K.

Cell Signal. 2011 Oct;23(10):1563-77. doi: 10.1016/j.cellsig.2011.04.009. Epub 2011 May 6.

PMID:
21627988
36.

Status of research on matrix metalloproteinases (MMPs) in India.

Bulbule A, Saraswati S, Kundu GC.

Expert Opin Ther Targets. 2011 Jun;15(6):671-5. doi: 10.1517/14728222.2011.576673. Epub 2011 Apr 11.

PMID:
21476880
37.
38.

p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression.

Kumar V, Behera R, Lohite K, Karnik S, Kundu GC.

Cancer Res. 2010 Dec 15;70(24):10381-91. doi: 10.1158/0008-5472.CAN-10-1470. Epub 2010 Oct 27.

39.
40.

Isolation, structure, and functional elucidation of a modified pentapeptide, cysteine protease inhibitor (CPI-2081) from Streptomyces species 2081 that exhibit inhibitory effect on cancer cell migration.

Singh JP, Tamang S, Rajamohanan PR, Jima NC, Chakraborty G, Kundu GC, Gaikwad SM, Khan MI.

J Med Chem. 2010 Jul 22;53(14):5121-8. doi: 10.1021/jm9014179.

PMID:
20552970
42.

Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.

Behera R, Kumar V, Lohite K, Karnik S, Kundu GC.

Carcinogenesis. 2010 Feb;31(2):192-200. doi: 10.1093/carcin/bgp289. Epub 2009 Nov 19.

PMID:
19926637
43.

Alcohol, signaling, and ECM turnover.

Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC, Meyer C, Meindl-Beinker NM.

Alcohol Clin Exp Res. 2010 Jan;34(1):4-18. doi: 10.1111/j.1530-0277.2009.01060.x. Epub 2009 Oct 23. Review.

PMID:
19860812
44.

Prostaglandin E2 regulates tumor angiogenesis in prostate cancer.

Jain S, Chakraborty G, Raja R, Kale S, Kundu GC.

Cancer Res. 2008 Oct 1;68(19):7750-9. doi: 10.1158/0008-5472.CAN-07-6689.

45.

Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression.

Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R, Kundu GC.

Mol Med Rep. 2008 Sep-Oct;1(5):641-6. doi: 10.3892/mmr_00000005.

PMID:
21479462
46.

Down-regulation of osteopontin attenuates breast tumour progression in vivo.

Chakraborty G, Jain S, Patil TV, Kundu GC.

J Cell Mol Med. 2008 Dec;12(6A):2305-18. doi: 10.1111/j.1582-4934.2008.00263.x. Epub 2008 Feb 4.

47.

Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.

Chakraborty G, Jain S, Kundu GC.

Cancer Res. 2008 Jan 1;68(1):152-61. doi: 10.1158/0008-5472.CAN-07-2126.

48.
49.

The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis.

Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC.

Curr Mol Med. 2006 Dec;6(8):819-30. Review.

PMID:
17168734
50.

Osteopontin: an emerging therapeutic target for anticancer therapy.

Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC.

Expert Opin Ther Targets. 2007 Jan;11(1):81-90. Review.

PMID:
17150036

Supplemental Content

Loading ...
Support Center